Yesterday marked 100 days since President Trump announced his drug pricing blueprint, the basic goal of which is to “lower prices” somehow. How successful has it been?
In thinking about this question, it is useful to remind oneself that drug production and distribution is largely market-based, and the lesson of the market framework is that prices fall only if there is an increase in supply, a decrease in demand, or a reduction in taxes and other overhead-like costs.
